+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Hepatocytes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 316 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5938869
Description Jump to:
Unveiling Opportunities, Challenges, and Country-wise Insights

Global Market Overview:

The global primary hepatocytes market is poised for significant growth, projected to reach a value of US$ 410 Mn by 2031, with an estimated Compound Annual Growth Rate (CAGR) of 8.0% over the next decade. This promising trajectory reflects the increasing demand for primary hepatocytes, driven by their crucial role in drug development, testing, and the development of new cancer treatments.

Opportunities for Primary Hepatocyte Manufacturers:

The routine adoption of hepatocytes for analyzing potential medication candidates accelerates the development of novel medicines and expedites their entry into clinical trials. The reliability of testing models significantly influences the success of developing novel medication therapies, emphasizing the pivotal role of hepatocytes in this process.

Advancements in technology are progressively reducing the reliance on animal models, favoring increasingly in vivo-like systems. This trend is expected to drive the demand for primary hepatocytes in the foreseeable future.

The growing prevalence of cancer and the escalating demand for cancer therapy have spurred research involving primary hepatocytes. Personalized medicine, which offers tailored treatment options based on individual patient characteristics, relies on primary hepatocytes for the development of personalized medications. Consequently, the market for primary hepatocytes has witnessed parallel growth alongside the rise in demand for personalized therapeutics.

Liver transplantation remains the optimal treatment for hepatic illness caused by various factors such as viruses, oncogenes, medications, or surgical removal. However, the scarcity of suitable liver donors presents challenges in meeting medical demands. To address this issue, alternative options such as hepatocyte transplantation are being explored, driving immediate demand for primary hepatocytes and fostering market development.

Stringent regulations set by various regulatory bodies emphasize ensuring the well-being of animals used in experiments. These regulations, coupled with researchers' self-imposed limits, have led to an increased demand for in-vivo models, presenting opportunities for primary hepatocyte providers to meet these regulatory standards and cater to the growing market demand.

Challenges Impacting Demand:

Despite the promising growth outlook, challenges persist in maintaining the demand for primary hepatocytes. Availability of other cell types for drug screening, along with the high risk of contamination and the intricate maintenance requirements of hepatocytes, pose constraints on market expansion. Additionally, the limited lifespan of freshly-isolated hepatocytes and the susceptibility to contamination hinder their widespread adoption.

Country-wise Insights:

  • United States: With approximately 84.7% market share in the North American primary hepatocytes culture market, the U.S. presents a lucrative landscape fueled by increasing investments in R&D programs and strategic business expansions.
  • Germany: Holding the largest market share in Europe, Germany benefits from the presence of major industry players, fostering accessibility and steady growth in the primary hepatocytes market.
  • China: Emerging as a prominent market, China exhibits substantial growth potential driven by extensive research activities, collaborative initiatives, and significant R&D investments.
  • India: With a considerable share in the South Asia primary hepatocytes market, India showcases a growing adoption of modern medicines and newer therapies, supported by increasing affordability and acceptance of biological drugs.
Competitive Landscape: Leading providers such as Thermo Fisher Scientific, Corning Inc., Lonza, and others are strategically positioning themselves through alliances, product launches, patents, and acquisitions to capitalize on the burgeoning opportunities in the primary hepatocytes industry.

Key Companies Profiled in the market include:

  • Thermo Fisher Scientific
  • Corning Inc.
  • Lonza
  • Axol Bioscience Ltd.
  • LifeNet Health
  • SEKISUI XenoTech, LLC
  • Cytes Biotechnologies
  • Cell Biologics, Inc.
  • ZenBio, Inc.
  • BioIVT.
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Takara Bio Inc.
  • Kosheeka

Key Segments Covered in Primary Hepatocytes Industry Survey

Primary Hepatocytes Market by Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

Primary Hepatocytes Market by Species:

  • Humans
  • Rats
  • Mice
  • Dogs
  • Monkeys
  • Horses
  • Others

Primary Hepatocytes Market by Application or Assay:

  • Cell Viability Assays
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assays
  • In Vitro Intrinsic Clearance
  • Phospholipoids Assays
  • Others

Primary Hepatocytes Market by End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

Primary Hepatocytes Market by Region:

  • North America Primary Hepatocytes Market
  • Latin America Primary Hepatocytes Market
  • Europe Primary Hepatocytes Market
  • South Asia Primary Hepatocytes Market
  • East Asia Primary Hepatocytes Market
  • Oceania Primary Hepatocytes Market
  • The Middle East & Africa Primary Hepatocytes Market


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Primary Hepatocytes Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Production Output and Trade Statistics, 2018 - 2023
3.1. Global Primary Hepatocytes Market Production Output, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2023
3.1.1. North America
3.1.2. Europe x`
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2018 - 2023
4.1. Global Average Price Analysis, by Product/ Species/ Application or Assay/ End User, US$ Per Unit, 2018 - 2023
4.2. Prominent Factor Affecting Primary Hepatocytes Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit
5. Global Primary Hepatocytes Market Outlook, 2018 - 2031
5.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Cryopreserved Suspension Hepatocytes
5.1.1.2. Fresh Suspension Hepatocytes
5.1.1.3. 3D (Spheroid) Hepatocytes
5.1.1.4. Expanded Hepatocytes (Plateable)
5.1.1.5. Non-characterized Hepatocytes
5.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Humans
5.2.1.2. Rats
5.2.1.3. Mice
5.2.1.4. Dogs
5.2.1.5. Monkeys
5.2.1.6. Horses
5.2.1.7. Others
5.3. Global Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Cell Viability Assays
5.3.1.2. Cytochrome Enzyme Activity
5.3.1.3. High Content Cytotoxicity
5.3.1.4. Transporter Inhibition Assays
5.3.1.5. In Vitro Intrinsic Clearance
5.3.1.6. Phospholipoids Assays
5.3.1.7. Others
5.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Biopharmaceutical Companies
5.4.1.2. Academic and Research Institutes
5.4.1.3. Contract Research Organizations
5.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Primary Hepatocytes Market Outlook, 2018 - 2031
6.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Cryopreserved Suspension Hepatocytes
6.1.1.2. Fresh Suspension Hepatocytes
6.1.1.3. 3D (Spheroid) Hepatocytes
6.1.1.4. Expanded Hepatocytes (Plateable)
6.1.1.5. Non-characterized Hepatocytes
6.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Humans
6.2.1.2. Rats
6.2.1.3. Mice
6.2.1.4. Dogs
6.2.1.5. Monkeys
6.2.1.6. Horses
6.2.1.7. Others
6.3. North America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Cell Viability Assays
6.3.1.2. Cytochrome Enzyme Activity
6.3.1.3. High Content Cytotoxicity
6.3.1.4. Transporter Inhibition Assays
6.3.1.5. In Vitro Intrinsic Clearance
6.3.1.6. Phospholipoids Assays
6.3.1.7. Others
6.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Biopharmaceutical Companies
6.4.1.2. Academic and Research Institutes
6.4.1.3. Contract Research Organizations
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.3. U.S. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.7. Canada Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Primary Hepatocytes Market Outlook, 2018 - 2031
7.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Cryopreserved Suspension Hepatocytes
7.1.1.2. Fresh Suspension Hepatocytes
7.1.1.3. 3D (Spheroid) Hepatocytes
7.1.1.4. Expanded Hepatocytes (Plateable)
7.1.1.5. Non-characterized Hepatocytes
7.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Humans
7.2.1.2. Rats
7.2.1.3. Mice
7.2.1.4. Dogs
7.2.1.5. Monkeys
7.2.1.6. Horses
7.2.1.7. Others
7.3. Europe Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Cell Viability Assays
7.3.1.2. Cytochrome Enzyme Activity
7.3.1.3. High Content Cytotoxicity
7.3.1.4. Transporter Inhibition Assays
7.3.1.5. In Vitro Intrinsic Clearance
7.3.1.6. Phospholipoids Assays
7.3.1.7. Others
7.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Biopharmaceutical Companies
7.4.1.2. Academic and Research Institutes
7.4.1.3. Contract Research Organizations
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.3. Germany Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.7. U.K. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.11. France Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.13. Italy Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.14. Italy Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.15. Italy Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.16. Italy Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.17. Turkey Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.18. Turkey Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.19. Turkey Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.20. Turkey Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.23. Russia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.27. Rest of Europe Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Primary Hepatocytes Market Outlook, 2018 - 2031
8.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Cryopreserved Suspension Hepatocytes
8.1.1.2. Fresh Suspension Hepatocytes
8.1.1.3. 3D (Spheroid) Hepatocytes
8.1.1.4. Expanded Hepatocytes (Plateable)
8.1.1.5. Non-characterized Hepatocytes
8.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Humans
8.2.1.2. Rats
8.2.1.3. Mice
8.2.1.4. Dogs
8.2.1.5. Monkeys
8.2.1.6. Horses
8.2.1.7. Others
8.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Cell Viability Assays
8.3.1.2. Cytochrome Enzyme Activity
8.3.1.3. High Content Cytotoxicity
8.3.1.4. Transporter Inhibition Assays
8.3.1.5. In Vitro Intrinsic Clearance
8.3.1.6. Phospholipoids Assays
8.3.1.7. Others
8.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Biopharmaceutical Companies
8.4.1.2. Academic and Research Institutes
8.4.1.3. Contract Research Organizations
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.3. China Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.7. Japan Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.11. South Korea Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.15. India Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.19. Southeast Asia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Primary Hepatocytes Market Outlook, 2018 - 2031
9.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.1.1. Key Highlights
9.1.1.1. Cryopreserved Suspension Hepatocytes
9.1.1.2. Fresh Suspension Hepatocytes
9.1.1.3. 3D (Spheroid) Hepatocytes
9.1.1.4. Expanded Hepatocytes (Plateable)
9.1.1.5. Non-characterized Hepatocytes
9.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.2.1. Key Highlights
9.2.1.1. Humans
9.2.1.2. Rats
9.2.1.3. Mice
9.2.1.4. Dogs
9.2.1.5. Monkeys
9.2.1.6. Horses
9.2.1.7. Others
9.3. Latin America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.3.1. Key Highlights
9.3.1.1. Cell Viability Assays
9.3.1.2. Cytochrome Enzyme Activity
9.3.1.3. High Content Cytotoxicity
9.3.1.4. Transporter Inhibition Assays
9.3.1.5. In Vitro Intrinsic Clearance
9.3.1.6. Phospholipoids Assays
9.3.1.7. Others
9.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.4.1. Key Highlights
9.4.1.1. Biopharmaceutical Companies
9.4.1.2. Academic and Research Institutes
9.4.1.3. Contract Research Organizations
9.4.2. BPS Analysis/Market Attractiveness Analysis
9.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1. Key Highlights
9.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.3. Brazil Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.7. Mexico Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.9. Argentina Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.10. Argentina Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.11. Argentina Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.12. Argentina Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.13. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.14. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.15. Rest of Latin America Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.1.16. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Primary Hepatocytes Market Outlook, 2018 - 2031
10.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.1.1. Key Highlights
10.1.1.1. Cryopreserved Suspension Hepatocytes
10.1.1.2. Fresh Suspension Hepatocytes
10.1.1.3. 3D (Spheroid) Hepatocytes
10.1.1.4. Expanded Hepatocytes (Plateable)
10.1.1.5. Non-characterized Hepatocytes
10.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.2.1. Key Highlights
10.2.1.1. Humans
10.2.1.2. Rats
10.2.1.3. Mice
10.2.1.4. Dogs
10.2.1.5. Monkeys
10.2.1.6. Horses
10.2.1.7. Others
10.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.3.1. Key Highlights
10.3.1.1. Cell Viability Assays
10.3.1.2. Cytochrome Enzyme Activity
10.3.1.3. High Content Cytotoxicity
10.3.1.4. Transporter Inhibition Assays
10.3.1.5. In Vitro Intrinsic Clearance
10.3.1.6. Phospholipoids Assays
10.3.1.7. Others
10.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.4.1. Key Highlights
10.4.1.1. Biopharmaceutical Companies
10.4.1.2. Academic and Research Institutes
10.4.1.3. Contract Research Organizations
10.4.2. BPS Analysis/Market Attractiveness Analysis
10.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1. Key Highlights
10.5.1.1. GCC Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.2. GCC Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.3. GCC Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.4. GCC Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.7. South Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.8. South Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.9. Egypt Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.10. Egypt Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.11. Egypt Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.12. Egypt Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.15. Nigeria Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.1.20. Rest of Middle East & Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. Product vs Application or Assay Heatmap
11.2. Company Market Share Analysis, 2022
11.3. Competitive Dashboard
11.4. Company Profiles
11.4.1. Thermo Fisher Scientific
11.4.1.1. Company Overview
11.4.1.2. Product Portfolio
11.4.1.3. Financial Overview
11.4.1.4. Business Strategies and Development
11.4.2. Corning Inc.
11.4.2.1. Company Overview
11.4.2.2. Product Portfolio
11.4.2.3. Financial Overview
11.4.2.4. Business Strategies and Development
11.4.3. Lonza
11.4.3.1. Company Overview
11.4.3.2. Product Portfolio
11.4.3.3. Financial Overview
11.4.3.4. Business Strategies and Development
11.4.4. Axol Bioscience Ltd.
11.4.4.1. Company Overview
11.4.4.2. Product Portfolio
11.4.4.3. Financial Overview
11.4.4.4. Business Strategies and Development
11.4.5. LifeNet Health
11.4.5.1. Company Overview
11.4.5.2. Product Portfolio
11.4.5.3. Financial Overview
11.4.5.4. Business Strategies and Development
11.4.6. SEKISUI XenoTech, LLC
11.4.6.1. Company Overview
11.4.6.2. Product Portfolio
11.4.6.3. Financial Overview
11.4.6.4. Business Strategies and Development
11.4.7. Cytes Biotechnologies
11.4.7.1. Company Overview
11.4.7.2. Product Portfolio
11.4.7.3. Financial Overview
11.4.7.4. Business Strategies and Development
11.4.8. Cell Biologics, Inc.
11.4.8.1. Company Overview
11.4.8.2. Product Portfolio
11.4.8.3. Financial Overview
11.4.8.4. Business Strategies and Development
11.4.9. ZenBio, Inc.
11.4.9.1. Company Overview
11.4.9.2. Product Portfolio
11.4.9.3. Financial Overview
11.4.9.4. Business Strategies and Development
11.4.10. BioIVT.
11.4.10.1. Company Overview
11.4.10.2. Product Portfolio
11.4.10.3. Financial Overview
11.4.10.4. Business Strategies and Development
11.4.11. ScienCell Research Laboratories, Inc.
11.4.11.1. Company Overview
11.4.11.2. Product Portfolio
11.4.11.3. Financial Overview
11.4.11.4. Business Strategies and Development
11.4.12. Kerafast
11.4.12.1. Company Overview
11.4.12.2. Product Portfolio
11.4.12.3. Financial Overview
11.4.12.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations

Companies Mentioned

  • Thermo Fisher Scientific
  • Corning Inc.
  • Lonza
  • Axol Bioscience Ltd.
  • LifeNet Health
  • SEKISUI XenoTech, LLC
  • Cytes Biotechnologies
  • Cell Biologics, Inc.
  • ZenBio, Inc.
  • BioIVT.
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Takara Bio Inc.
  • Kosheeka

Methodology

Loading
LOADING...

Related Topics

Related Reports

Humanized Liver Mice Model Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Humanized Liver Mice Model Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 198 Pages
  • Global
Oncology Mice Models Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Oncology Mice Models Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
Human Liver Models - Global Strategic Business Report - Product Image

Human Liver Models - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Humanized Mouse and Rat Model - Global Strategic Business Report - Product Image

Humanized Mouse and Rat Model - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Edema Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031 - Product Image

Edema Clinical Trials Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031

  • Report
  • 115 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.